Next Article in Journal
Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients
Next Article in Special Issue
Scars or Regeneration?—Dermal Fibroblasts as Drivers of Diverse Skin Wound Responses
Previous Article in Journal
Immune Functional Analysis of Chitin Deacetylase 3 from the Asian Citrus Psyllid Diaphorina citri
Previous Article in Special Issue
Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options
Open AccessArticle

Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C

1
Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka 569-8686, Japan
2
Department of Innovative Medicine, Osaka Medical College, Takatsuki-City, Osaka 569-8686, Japan
3
NAGATA Eye Clinic, Nara-City, Nara 631-0844, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(1), 63; https://doi.org/10.3390/ijms21010063
Received: 24 November 2019 / Revised: 17 December 2019 / Accepted: 17 December 2019 / Published: 20 December 2019
(This article belongs to the Special Issue Recent Advances in Pathophysiology of Fibrosis and Scarring)
Regorafenib eye drops were developed for treating age-related macular degeneration. This study aimed to investigate the effects of this multi-kinase inhibitor on intraocular pressure (IOP), bleb formation, and conjunctival changes in a canine filtration surgery model. Glaucoma filtration surgery models were created in 24 eyes of 24 beagles. In experiment 1 (Ex 1), regorafenib eye drops (regorafenib group: n = 6) or a vehicle (control group, n = 6) were instilled twice daily for 4 weeks postoperatively. In experiment 2 (Ex 2), regorafenib eye drops were instilled as in Ex 1 (regorafenib group: n = 6) for 12 weeks while conventional intraoperative mitomycin-C (MMC) was utilized (MMC group: n = 6), In Ex 1, only the regorafenib group showed significant IOP reduction with a significantly higher bleb score. Subconjunctival area, collagen density, vessels, and cells showing proliferation and differentiation were lower in subconjunctival tissue in the regorafenib group. In Ex 2, no significant difference was found in IOP reduction and bleb formation between the regorafenib and MMC groups; bleb walls were significantly thicker and collagen density and vessels were higher in the regorafenib group; and no differences were observed in the above-mentioned cells. Thus, regorafenib might be a better alternative to MMC for creating thicker and less ischemic blebs in glaucoma filtration surgery. View Full-Text
Keywords: beagles; glaucoma; multi-kinase inhibitor; regorafenib; trabeculectomy beagles; glaucoma; multi-kinase inhibitor; regorafenib; trabeculectomy
Show Figures

Graphical abstract

MDPI and ACS Style

Nemoto, E.; Kojima, S.; Sugiyama, T.; Jin, D.; Takai, S.; Maeda, M.; Kohmoto, R.; Ueki, M.; Oku, H.; Ikeda, T. Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C. Int. J. Mol. Sci. 2020, 21, 63.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop